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The concept of ‘‘G2 checkpoint abrogation’’ in combination with
various chemotherapeutic drugs is currently successfully
explored in clinical trials. The anti-cancer drug UCN-01 allows
the entry into mitosis in the presence of DNA damage selectively
in p53 defective tumor cells.
We show here that this leads to a mitotic arrest and to the
activation of a branch of the mitotic spindle checkpoint that mon-
itors the lack of tension across kinetochores involving the func-
tion of Mad2, Bub1, BubR1, Mps1, Aurora B and survivin.
Subsequently mitotic cell death, also known as ‘‘mitotic catastro-
phe’’, is induced, which potentiates the efficacy of standard che-
motherapy. Interestingly, mitotic cell death is associated with the
activation of the mitochondria associated apoptosis pathway,
thus, we refer to it as mitotic apoptosis. Importantly, while the
mitotic arrest in response to UCN-01 is dependent on the spindle
checkpoint, only the checkpoint component Mad2 is required for
the execution of mitotic apoptosis suggesting that Mad2 might
have an additional function as a pro-apoptotic protein. Signifi-
cantly, the mitotic apoptosis is counteracted by a survivin depen-
dent survival pathway. Thus, the mitotic apoptosis is a result of a
balance between pro- and anti-apoptotic pathways. Most impor-
tantly, pharmacologiocal interference with Aurora B, CDK1 or
PI3-kinase modulating the levels of survivin leads to a significant
increase of apoptosis in response to UCN-01. Thus, our results
suggest a highly improved strategy for anti-cancer treatment
using UCN-01 and abrogators of a mitotic survivin dependent sur-
vivial pathway without neglecting the selectivity of UCN-01 for
p53 defective cancer cells.
doi:10.1016/j.ejcsup.2006.04.036
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Research of the past 25 years resulted in the identification of a
number of infectious agents engaged in the etiology of in part
very common human cancers. Among the latter are cervical
cancer and hepatocellular carcinomas. Members of several dif-
ferent virus families possess oncogenic potential: these are pap-
illomaviruses (e.g. HPV 16 and 18), herpes group viruses
(Epstein-Barr virus and human herpesvirus type 8), Hepatitis B
and Hepatitis C virus, Human T-lymphotropic retrovirus type 1
(HTLV-1). Most of these agents contain oncogenes and act as
‘‘direct carcinogens’’. The functions of these oncogenes have
been partially characterized and will be discussed. Humans
and their cells infected by these viruses are commonly able to
cope with these infections by intra- and intercellular surveil-
lance mechanisms or by immunological interference. Cancer
development requires a modification of genes within the signal-
ling pathways regulating the intra- and intercellular defense.
Part of the modifications of cellular genes is also mediated by
viral oncogenes.
Besides direct carcinogenic functions via oncogenes, other
agents contribute to human cancer by rather indirect modes.
This seems to be the case in hepatitis B and C infections where
the induction of oxygen radicals apparently plays a significant
role in cancer induction. Human immunodeficiency viruses
(HIV) promote cancer induction by other viruses due to the
induction of immunosuppression. Possible other mechanisms
of indirect carcinogenesis by infectious agents will also be
discussed.
doi:10.1016/j.ejcsup.2006.04.037
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As a result of their oncotropism, oncolytic effect and low inflam-
matory activity, some autonomous parvoviruses open up new
prospects to the fight against cancer and were tested for their
safety in pilot phase I clinical trials. Preclinical studies in animal
models showed that the parvoviruses H-1PV and MVM are
endowed with a genuine oncosuppressive capacity, for which var-
ious tumours can be targets. However, the antineoplastic poten-
tial of these agents is insufficient, in many instances, for
tumours to irreversibly regress. Efforts are thus made to improve
the oncosuppressive activity of parvoviruses, using different
strategies. On the one hand, discrete modifications are intro-
duced into the parvoviral genome so as to keep its infectiousness
while stimulating its antineoplastic properties. Parvovirus
mutants were engineered so that their capacity for tumour cell
lysis or immune cell activation is enhanced. On the other hand,
parvoviruses are used as vectors to generate recombinants that
are able to deliver therapeutic transgenes in target cells. MVM
and H-1PV-based vectors transducing and expressing anti-angio-
genic and/or immunomodulating factors were more particularly
produced. Appropriate combinations of these recombinant vec-
tors were found to efficiently suppress highly vascularised
tumours, e.g. gliomas, in animal models. On the basis of these
data, the promise of the application of parvoviruses to cancer
viro- and gene therapy will be discussed.
doi:10.1016/j.ejcsup.2006.04.038
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Since several years it has been accepted that persistent infection
with certain (so called-high risk: HR) types of Human papillom-
aviruses (HPV) represents a strong risk factor for cervical cancer.
The most frequent HR HPV types 16 and 18 account for about
70% of this tumour, which is the second most frequent malig-
nancy in women worldwide. Several studies in animal papillo-
mavirus models revealed that protection against infection is
conferred by neutralizing antibodies directed against conforma-
tional epitopes of the major structural protein L1. Such antibod-
ies can most efficiently be induced by immunization with virus-
like particles (VLP) that assemble spontaneously following
expression of L1 in recombinant vectors. Large-scale production
of HPV 16 and 18 VLPs proved to be successful facilitating, a few
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